Athenex Ruling Helps Clarify FDA Drug Compounding Policy

On Aug. 1, 2019, the U.S. District Court for the District of Columbia affirmed the U.S. Food and Drug Administration's decision to exclude the bulk drug substance vasopressin from the agency's...

Already a subscriber? Click here to view full article